AarogyaAI aims to diagnose drug-resistant tuberculosis (DR-TB) using Artificial Intelligence in a few hours. We enable quick and accurate diagnosis of DR-TB so that the patient can be rightly prescribed effective drug combinations for treatment, instantly.
Our co-founders, Praapti and Avlokita, are motivated by their life experiences to develop a solution for the growing challenges of DR-TB. Praapti, grew up in a family of doctors and was motivated to address public health issues using her scientific training in infectious diseases. Avlokita, lost her grandmother to tuberculosis and wanted to be a part of the solution working towards eliminating this disease.
In India today, Tuberculosis affects 2.7 million people each year, and thousands of people die because of it. However, there is a disproportionate focus on solving micro problems in research which, do not translate into public application. Our aim is to bridge that gap.
As a young start-up in the space of healthcare technology, we have drawn on the experiences of our peers and relied on this growing community of entrepreneurs to navigate complexities in compliances, IP laws and taxes for startups in India. Through this community, we have also had the opportunity to share our vision, our story and where we want to go from here. We spoke to SET IMPACT about the challenges of tuberculosis eradication in India and where AI comes in. We were also in conversation with StartUps of London talking about how the Illumina Accelerator came at a time when we were looking for experience and resources in genome sequencing.
We are greatly inspired by Dr. Soumya Swaminathan, Chief Scientist at WHO and a tuberculosis physician. Dr.Swaminathan took a keen interest in our objectives and, is our mentor on this journey.